Licence agreement to develop ADCs for hard-to-treat cancers 

Cancer Abnormal Cells Nucleus Genetic Division Infection Microscope

Pheon Therapeutics, an antibody drug conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, has entered an exclusive licence agreement with Biocytogen Pharmaceuticals, a global biotech company focused on the discovery of novel antibody therapeutics.  

Under the terms of the agreement, Pheon will develop and commercialise an antibody developed using Biocytogen’s proprietary RenMice platforms. 

The new agreement expands Pheon’s ADC pipeline which boasts first-in-class and best-in-class ADCs to meet significant unmet clinical needs in oncology. Pheon launched in March 2022 with a $68 million Series A financing led by a strong leadership team of specialists in targeted oncology therapies and ADCs. 

Bertrand Damour, Chief Executive Officer of Pheon Therapeutics, said: “This licence agreement represents a significant expansion of Pheon’s pipeline, and it enhances our ability to successfully develop the next generation of ADCs. Biocytogen is a fantastic partner with groundbreaking technology that is well suited to our needs. We look forward to working with them and helping to find powerful therapies that can address the significant unmet patient need in solid tumours across a broad range of hard-to-treat cancers.”    

Dr Yuelei Shen, President and CEO of Biocytogen, said: “We are glad to collaborate with Pheon Therapeutics. Using RenMice, we have launched Project Integrum which aims to develop fully human therapeutic antibody molecules for 1000+ targets for the development of drugs in different modalities. The combination of our strengths in fully human antibody discovery with Pheon’s strengths in ADC technologies may accelerate the generation of differentiated novel therapeutics that can bring benefits to patients.” 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free